26.24 USD
-0.35 (-1.32%)
ACAD gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 528 industry peers in the Biotechnology industry. ACAD is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. ACAD has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
ACAD had positive earnings in the past year.
ACAD had a positive operating cash flow in the past year.
In the past 5 years ACAD always reported negative net income.
In the past 5 years ACAD always reported negative operating cash flow.
1.2 Ratios
ACAD has a Return On Assets of 19.63%. This is amongst the best in the industry. ACAD outperforms 96.97% of its industry peers.
With an excellent Return On Equity value of 28.47%, ACAD belongs to the best of the industry, outperforming 97.54% of the companies in the same industry.
The Return On Invested Capital of ACAD (7.66%) is better than 93.75% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.63% | ||
| ROE | 28.47% | ||
| ROIC | 7.66% |
ROA(3y)-13.43%
ROA(5y)-20.05%
ROE(3y)-13.54%
ROE(5y)-23.31%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 24.94%, ACAD belongs to the best of the industry, outperforming 94.89% of the companies in the same industry.
The Operating Margin of ACAD (9.02%) is better than 91.10% of its industry peers.
Looking at the Gross Margin, with a value of 91.92%, ACAD belongs to the top of the industry, outperforming 93.18% of the companies in the same industry.
ACAD's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.02% | ||
| PM (TTM) | 24.94% | ||
| GM | 91.92% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.57%
GM growth 5Y2.57%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ACAD is destroying value.
The number of shares outstanding for ACAD has been increased compared to 1 year ago.
Compared to 5 years ago, ACAD has more shares outstanding
There is no outstanding debt for ACAD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
ACAD has an Altman-Z score of 6.00. This indicates that ACAD is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 6.00, ACAD is doing good in the industry, outperforming 75.95% of the companies in the same industry.
There is no outstanding debt for ACAD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 6 |
ROIC/WACC0.87
WACC8.82%
2.3 Liquidity
A Current Ratio of 3.02 indicates that ACAD has no problem at all paying its short term obligations.
ACAD has a worse Current ratio (3.02) than 63.83% of its industry peers.
A Quick Ratio of 2.94 indicates that ACAD has no problem at all paying its short term obligations.
With a Quick ratio value of 2.94, ACAD is not doing good in the industry: 62.50% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.02 | ||
| Quick Ratio | 2.94 |
3. Growth
3.1 Past
ACAD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -14.10%.
The Revenue has grown by 121.75% in the past year. This is a very strong growth!
EPS 1Y (TTM)-14.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%110%
Revenue 1Y (TTM)121.75%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.27%
3.2 Future
ACAD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 39.40% yearly.
ACAD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.47% yearly.
EPS Next Y71.6%
EPS Next 2Y29.52%
EPS Next 3Y35.28%
EPS Next 5Y39.4%
Revenue Next Year11.07%
Revenue Next 2Y11.29%
Revenue Next 3Y11.08%
Revenue Next 5Y10.47%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 39.16, ACAD can be considered very expensive at the moment.
Based on the Price/Earnings ratio, ACAD is valued cheaply inside the industry as 91.48% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 27.25. ACAD is valued slightly more expensive when compared to this.
With a Price/Forward Earnings ratio of 32.59, ACAD can be considered very expensive at the moment.
ACAD's Price/Forward Earnings ratio is rather cheap when compared to the industry. ACAD is cheaper than 92.05% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.98, ACAD is valued a bit more expensive.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 39.16 | ||
| Fwd PE | 32.59 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ACAD is valued cheaper than 92.80% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, ACAD is valued cheaply inside the industry as 95.45% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 20.39 | ||
| EV/EBITDA | 28.24 |
4.3 Compensation for Growth
ACAD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of ACAD may justify a higher PE ratio.
A more expensive valuation may be justified as ACAD's earnings are expected to grow with 35.28% in the coming years.
PEG (NY)0.55
PEG (5Y)N/A
EPS Next 2Y29.52%
EPS Next 3Y35.28%
5. Dividend
5.1 Amount
No dividends for ACAD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:ACAD (1/13/2026, 1:10:21 PM)
26.24
-0.35 (-1.32%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners101.21%
Inst Owner Change-0.03%
Ins Owners0.26%
Ins Owner Change-3.63%
Market Cap4.44B
Revenue(TTM)1.05B
Net Income(TTM)261.17M
Analysts76.92
Price Target29.96 (14.18%)
Short Float %5.18%
Short Ratio5.57
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)96.34%
Min EPS beat(2)14.46%
Max EPS beat(2)178.22%
EPS beat(4)2
Avg EPS beat(4)20.1%
Min EPS beat(4)-109.07%
Max EPS beat(4)178.22%
EPS beat(8)5
Avg EPS beat(8)29%
EPS beat(12)7
Avg EPS beat(12)26.97%
EPS beat(16)10
Avg EPS beat(16)24.21%
Revenue beat(2)0
Avg Revenue beat(2)-1.06%
Min Revenue beat(2)-1.19%
Max Revenue beat(2)-0.93%
Revenue beat(4)1
Avg Revenue beat(4)-2.59%
Min Revenue beat(4)-8.33%
Max Revenue beat(4)0.08%
Revenue beat(8)3
Avg Revenue beat(8)-1.62%
Revenue beat(12)5
Avg Revenue beat(12)-0.37%
Revenue beat(16)6
Avg Revenue beat(16)-1.45%
PT rev (1m)0.36%
PT rev (3m)1.08%
EPS NQ rev (1m)-0.35%
EPS NQ rev (3m)5.79%
EPS NY rev (1m)-1.14%
EPS NY rev (3m)43.73%
Revenue NQ rev (1m)-0.04%
Revenue NQ rev (3m)2.28%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.01%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 39.16 | ||
| Fwd PE | 32.59 | ||
| P/S | 4.24 | ||
| P/FCF | 20.39 | ||
| P/OCF | 13.97 | ||
| P/B | 4.84 | ||
| P/tB | 5.51 | ||
| EV/EBITDA | 28.24 |
EPS(TTM)0.67
EY2.55%
EPS(NY)0.81
Fwd EY3.07%
FCF(TTM)1.29
FCFY4.9%
OCF(TTM)1.88
OCFY7.16%
SpS6.19
BVpS5.42
TBVpS4.76
PEG (NY)0.55
PEG (5Y)N/A
Graham Number9.04
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.63% | ||
| ROE | 28.47% | ||
| ROCE | 9.69% | ||
| ROIC | 7.66% | ||
| ROICexc | 58.65% | ||
| ROICexgc | 479.54% | ||
| OM | 9.02% | ||
| PM (TTM) | 24.94% | ||
| GM | 91.92% | ||
| FCFM | 20.79% |
ROA(3y)-13.43%
ROA(5y)-20.05%
ROE(3y)-13.54%
ROE(5y)-23.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.57%
GM growth 5Y2.57%
F-Score4
Asset Turnover0.79
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 711.57% | ||
| Cap/Sales | 9.55% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 292.92% | ||
| Profit Quality | 83.36% | ||
| Current Ratio | 3.02 | ||
| Quick Ratio | 2.94 | ||
| Altman-Z | 6 |
F-Score4
WACC8.82%
ROIC/WACC0.87
Cap/Depr(3y)241.55%
Cap/Depr(5y)203.25%
Cap/Sales(3y)567.7%
Cap/Sales(5y)341.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%110%
EPS Next Y71.6%
EPS Next 2Y29.52%
EPS Next 3Y35.28%
EPS Next 5Y39.4%
Revenue 1Y (TTM)121.75%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.27%
Revenue Next Year11.07%
Revenue Next 2Y11.29%
Revenue Next 3Y11.08%
Revenue Next 5Y10.47%
EBIT growth 1Y50.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.82%
EBIT Next 3Y27.27%
EBIT Next 5Y43.9%
FCF growth 1Y264.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y443.26%
OCF growth 3YN/A
OCF growth 5YN/A
ACADIA PHARMACEUTICALS INC / ACAD FAQ
What is the fundamental rating for ACAD stock?
ChartMill assigns a fundamental rating of 5 / 10 to ACAD.
What is the valuation status of ACADIA PHARMACEUTICALS INC (ACAD) stock?
ChartMill assigns a valuation rating of 6 / 10 to ACADIA PHARMACEUTICALS INC (ACAD). This can be considered as Fairly Valued.
Can you provide the profitability details for ACADIA PHARMACEUTICALS INC?
ACADIA PHARMACEUTICALS INC (ACAD) has a profitability rating of 6 / 10.
What are the PE and PB ratios of ACADIA PHARMACEUTICALS INC (ACAD) stock?
The Price/Earnings (PE) ratio for ACADIA PHARMACEUTICALS INC (ACAD) is 39.16 and the Price/Book (PB) ratio is 4.84.
Can you provide the financial health for ACAD stock?
The financial health rating of ACADIA PHARMACEUTICALS INC (ACAD) is 7 / 10.